Cargando…
Nerve Growth Factor Compromise in Down Syndrome
The basal forebrain cholinergic system relies on trophic support by nerve growth factor (NGF) to maintain its phenotype and function. In Alzheimer’s disease (AD), basal forebrain cholinergic neurons (BFCNs) undergo progressive atrophy, suggesting a deficit in NGF trophic support. Within the central...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381049/ https://www.ncbi.nlm.nih.gov/pubmed/34434101 http://dx.doi.org/10.3389/fnagi.2021.719507 |
_version_ | 1783741291837784064 |
---|---|
author | Do Carmo, Sonia Kannel, Benjamin Cuello, A. Claudio |
author_facet | Do Carmo, Sonia Kannel, Benjamin Cuello, A. Claudio |
author_sort | Do Carmo, Sonia |
collection | PubMed |
description | The basal forebrain cholinergic system relies on trophic support by nerve growth factor (NGF) to maintain its phenotype and function. In Alzheimer’s disease (AD), basal forebrain cholinergic neurons (BFCNs) undergo progressive atrophy, suggesting a deficit in NGF trophic support. Within the central nervous system, NGF maturation and degradation are tightly regulated by an activity-dependent metabolic cascade. Here, we present a brief overview of the characteristics of Alzheimer’s pathology in Down syndrome (DS) with an emphasis on this NGF metabolic pathway’s disruption during the evolving Alzheimer’s pathology. Such NGF dysmetabolism is well-established in Alzheimer’s brains with advanced pathology and has been observed in mild cognitive impairment (MCI) and non-demented individuals with elevated brain amyloid levels. As individuals with DS inexorably develop AD, we then review findings that support the existence of a similar NGF dysmetabolism in DS coinciding with atrophy of the basal forebrain cholinergic system. Lastly, we discuss the potential of NGF-related biomarkers as indicators of an evolving Alzheimer’s pathology in DS. |
format | Online Article Text |
id | pubmed-8381049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83810492021-08-24 Nerve Growth Factor Compromise in Down Syndrome Do Carmo, Sonia Kannel, Benjamin Cuello, A. Claudio Front Aging Neurosci Neuroscience The basal forebrain cholinergic system relies on trophic support by nerve growth factor (NGF) to maintain its phenotype and function. In Alzheimer’s disease (AD), basal forebrain cholinergic neurons (BFCNs) undergo progressive atrophy, suggesting a deficit in NGF trophic support. Within the central nervous system, NGF maturation and degradation are tightly regulated by an activity-dependent metabolic cascade. Here, we present a brief overview of the characteristics of Alzheimer’s pathology in Down syndrome (DS) with an emphasis on this NGF metabolic pathway’s disruption during the evolving Alzheimer’s pathology. Such NGF dysmetabolism is well-established in Alzheimer’s brains with advanced pathology and has been observed in mild cognitive impairment (MCI) and non-demented individuals with elevated brain amyloid levels. As individuals with DS inexorably develop AD, we then review findings that support the existence of a similar NGF dysmetabolism in DS coinciding with atrophy of the basal forebrain cholinergic system. Lastly, we discuss the potential of NGF-related biomarkers as indicators of an evolving Alzheimer’s pathology in DS. Frontiers Media S.A. 2021-08-09 /pmc/articles/PMC8381049/ /pubmed/34434101 http://dx.doi.org/10.3389/fnagi.2021.719507 Text en Copyright © 2021 Do Carmo, Kannel and Cuello. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Do Carmo, Sonia Kannel, Benjamin Cuello, A. Claudio Nerve Growth Factor Compromise in Down Syndrome |
title | Nerve Growth Factor Compromise in Down Syndrome |
title_full | Nerve Growth Factor Compromise in Down Syndrome |
title_fullStr | Nerve Growth Factor Compromise in Down Syndrome |
title_full_unstemmed | Nerve Growth Factor Compromise in Down Syndrome |
title_short | Nerve Growth Factor Compromise in Down Syndrome |
title_sort | nerve growth factor compromise in down syndrome |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381049/ https://www.ncbi.nlm.nih.gov/pubmed/34434101 http://dx.doi.org/10.3389/fnagi.2021.719507 |
work_keys_str_mv | AT docarmosonia nervegrowthfactorcompromiseindownsyndrome AT kannelbenjamin nervegrowthfactorcompromiseindownsyndrome AT cuelloaclaudio nervegrowthfactorcompromiseindownsyndrome |